Visão geral da empresa
A biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of pharmaceutical products aimed at treating human diseases, Lexicon Pharmaceuticals, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where innovation in drug discovery is paramount for addressing complex medical conditions. The company's scale is defined by a market capitalization of $745.68M, an annual revenue of $49.80M, and a workforce consisting of 81 employees. These valuation and revenue figures indicate a mid-sized biotechnology entity that is currently in a growth or development phase rather than a mature, cash-flow positive operation typical of large-cap pharmaceutical giants. The relatively small employee count combined with a significant market cap suggests a company that relies heavily on intellectual property and pipeline assets rather than broad-scale manufacturing or sales infrastructure to generate its current valuation.
Saúde financeira
The company reported a revenue of $49.80M over the trailing twelve months, yet it posted a net income of -$50.341M and an EBITDA of -$48.29M, revealing a substantial gap between top-line generation and bottom-line profitability that points to a heavy cost structure associated with research, development, and potentially high overhead costs relative to current sales. The free cash flow stands at -$47.815248M, indicating that the company is burning cash at a significant rate, which limits its immediate financial flexibility and suggests a reliance on external capital sources or existing cash reserves to fund operations. Margin analysis shows a gross margin of 86.8%, reflecting high efficiency in production or low cost of goods sold for its drug candidates, while the operating margin of -269.1% and profit margin of -101.1% demonstrate that operating expenses and costs of sales are vastly exceeding total revenue, a common characteristic in early-stage biotechnology firms before commercial products achieve widespread adoption. On the balance sheet, the company holds $96.23M in cash against $62.24M in debt, resulting in a debt-to-equity ratio of 57.87, which indicates a leveraged position where equity is significantly smaller than the debt load, though the substantial cash cushion provides a buffer against interest obligations. Liquidity is robust, evidenced by a current ratio of 4.88, which signals that the company possesses more than four times the current assets needed to cover its short-term liabilities, ensuring it can meet its immediate financial obligations without distress. Return on equity is -39.7% and return on assets is -12.6%, metrics that reveal that management is currently generating negative returns on the capital invested, a typical scenario for companies in the development stage where losses are incurred to build pipeline value rather than to distribute profits to shareholders.
Avaliação de valorização
Valuation multiples for the company include a trailing P/E ratio that is not applicable due to losses and a forward P/E of -8.46, implying that the market expects earnings to remain negative or for the company to require time before achieving profitability, as a negative forward P/E generally signals an expectation of continued losses or a turnaround in earnings trajectory. The price-to-book ratio is 5.95, indicating that the market is valuing the company at nearly six times its book value, which suggests a significant market premium assigned to the company's intangible assets, such as its drug pipeline and intellectual property, rather than its tangible physical assets. Alternative valuation metrics include a price-to-sales ratio of 14.97 and an EV/EBITDA of -14.74, suggesting that investors are pricing the stock based on revenue potential and asset quality rather than current earnings power, as the negative EV/EBITDA reinforces the company's unprofitable status. The stock has traded between a 52-week low of $0.45 and a 52-week high of $1.84, meaning the current trading price sits somewhere within this volatile range, reflecting the high uncertainty surrounding the success of its drug candidates. With a beta of 0.95, the company exhibits price volatility that closely mirrors the broader market, indicating that its stock price moves in tandem with general market sentiment rather than displaying extreme defensive or aggressive characteristics relative to the S&P 500.
Growth & Income
The company experienced a revenue growth of -79.3% year over year, while earnings growth is not applicable due to the absence of positive earnings, indicating that the business is contracting in terms of revenue recognition, likely due to the transition between product lifecycle stages or the loss of exclusivity on key assets, rather than organic expansion. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests its limited earnings and cash reserves back into its research and development efforts to advance its drug candidates rather than distributing income to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete lack of current income generation, reflecting a strategic focus on long-term asset building and clinical progress rather than short-term financial returns or shareholder payouts. This profile is typical for biotechnology firms in the development phase, where capital allocation is directed toward achieving regulatory approval and market entry for sotagliflozin and other potential treatments.